Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models

  • Mark Jit1,
  • Nadia Demarteau2,
  • Elamin Elbasha3,
  • Gary Ginsberg4,
  • Jane Kim5,
  • Naiyana Praditsitthikorn6,
  • Edina Sinanovic7 and
  • Raymond Hutubessy8Email author
Contributed equally
BMC Medicine20119:54

DOI: 10.1186/1741-7015-9-54

Received: 29 November 2010

Accepted: 12 May 2011

Published: 12 May 2011

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
29 Nov 2010 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
10 Jan 2011 Reviewed Reviewer Report - Maarten Postma
7 Feb 2011 Reviewed Reviewer Report - Jon Kim Andrus
17 Feb 2011 Reviewed Reviewer Report - Shalini Kulasingam
7 Mar 2011 Author responded Author comments - Raymond Hutubessy
Resubmission - Version 3
7 Mar 2011 Submitted Manuscript version 3
8 Mar 2011 Reviewed Reviewer Report - Maarten Postma
9 Mar 2011 Reviewed Reviewer Report - Jon Kim Andrus
17 Mar 2011 Reviewed Reviewer Report - Shalini Kulasingam
12 Apr 2011 Author responded Author comments - Raymond Hutubessy
Resubmission - Version 4
12 Apr 2011 Submitted Manuscript version 4
Publishing
12 May 2011 Editorially accepted
12 May 2011 Article published 10.1186/1741-7015-9-54

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Modelling and Economics Unit, Health Protection Agency
(2)
Health Economics, GlaxoSmithKline Biologicals
(3)
Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck & Co., Inc., UG1C-60
(4)
Medical Technology Assessment Sector, Ministry of Health
(5)
Harvard School of Public Health, Department of Health Policy and Management, Center for Health Decision Science
(6)
Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health
(7)
Health Economics Unit, School of Public Health & Family Medicine, University of Cape Town
(8)
Initiative for Vaccine Research, World Health Organization

Advertisement